Patients with depersonalization disorder experience episodes in which they have a feeling of detachment from themselves. Symptoms of depersonalization may occur in individuals who have other mental disorders, or who have various medical conditions, or who have taken certain medications. A woman developed depersonalization symptoms after initiation of minocycline therapy. Her symptoms ceased after treatment was stopped and recurred when she restarted the drug. Medications that have been associated with causing symptoms of depersonalization are presented and the postulated pathogenesis by which some of these drugs induced depersonalization symptoms is discussed. Medication-associated depersonalization symptoms typically resolve once the inducing drug has been withdrawn.
Psychiatric syndromes that consist of disruptions of aspects of consciousness, environmental awareness, identity, memory, or motor behavior are classified as dissociative disorders. 1 Depersonalization disorder is a dissociative disorder characterized by persistent or recurrent episodes in which the individual has a feeling of detachment or estrangement from one’s self. Although their reality testing remains intact, the person may feel like they are living in a dream or like an automation. Depersonalization disorder cannot be diagnosed if it is part of another psychiatric condition or if it is secondary to a medical disorder or if it is caused by a drug. 1–7 In contrast, transient depersonalization symptoms may occur in association with several mental disorders, medical conditions, or medications. 1–42
Minocycline is a semisynthetic tetracycline derivative that is well absorbed after oral administration. 43–45 Since it penetrates well into sebum, secondary to its high lipid solubility, it is commonly used in the treatment of acne vulgaris. 46 The potential profile of minocycline-associated adverse sequelae has been established. 43–51 Central nervous system-related side effects that may occur in patients treated with this medication include headaches, light-headedness, pseudotumor cerebri (also referred to as benign intracranial hypertension, which clinically presents with blurred vision and headache), and vestibular disturbances (such as ataxia, vertigo, and dizziness). 43–46,52–54
A young woman with minocycline-induced transient depersonalization symptoms is described. Her symptoms began after initiating treatment with minocycline, ceased after stopping the medication, and recurred after restarting the drug. Other medications that have been associated with causing symptoms of depersonalization are summarized and some of the postulated mechanisms for the pathogenesis of these drug-related symptoms are discussed.
* Symptoms of depersonalization, such as persistent or recurrent episodes in which the individual has a feeling of detachment or estrangement from one’s self, may occur in association with several medications.
* Hypersensitivity of the serotonin system, drug-related metabolic encephalopathy, panic disorder-related etiology, and substance-induced temporal disintegration possibly secondary to increased levels of brain activity have been hypothesized as possible mechanisms of pathogenesis for some of the medications associated with inducing depersonalization symptoms.
* Medication-associated depersonalization symptoms typically resolve once the inducing drug has been withdrawn.
1. Coons PM. The dissociative disorders: Rarely considered and underdiagnosed. Psychiatr Clin North Am 1998; 21: 637–648.
2. Simeon D, Gross S, Guralnik O, et al. Feeling unreal: 30 cases of DSM-III-R depersonalization disorder. Am J Psychiatry 1997; 154: 1107–1113.
3. Fichtner CG, Horevitz RP, Braun BG. Fluoxetine in depersonalization disorder. Am J Psychiatry 1992; 149: 1750–1751(letter).
4. Guralnik O, Schmeidler J, Simeon D. Feeling unreal: Cognitive processes in depersonalization. Am J Psychiatry 2000; 157: 103–109.
5. Lambert MV, Sierra M, Phillips ML, et al. The spectrum of organic depersonalization: A review plus four new cases. J Neuropsychiatry Clin Neurosci 2002; 14: 141–154.
6. Olson M. The out-of-body experience and other states of consciousness. Arch Psychiatr Nurs 1987; 1: 201–207.
7. Simeon D, Guralnik O, Gross S, et al. The detection and measurement of depersonalization disorder. J Nerv Ment Dis 1998; 186: 536–542.
8. Ryle A. The pathogenesis of depersonalisation. Br J Psychiatry 1988; 153: 405–406(letter).
9. Ackner B. Depersonalization: Part I—Aetiology and phenomenology. J Ment Sci 1954; 100: 838–853.
10. Cohen SI. The pathogenesis of depersonalisation: A hypothesis. Br J Psychiatry 1988; 152: 578(letter).
11. Noyes R Jr, Kletti R. Depersonalization in response to life-threatening danger. Compr Psychiatry 1977; 18: 375–384.
12. Ogata SN, Silk KR, Goodrich S, et al. Childhood sexual and physical abuse in adult patients with borderline personality disorder. Am J Psychiatry 1990; 147: 1008–1013.
13. Sedman G. An investigation of certain factors concerned in the aetiology of depersonalization. Acta Psychiatr Scand 1972; 48: 191–219.
14. Langs G, Fabisch H, Fabisch K, et al. Can cannabis trigger recurrent panic attacks in susceptible patients? Eur Psychiatry 1997; 12: 415–419.
15. Davison K. Episodic depersonalization: Observations on 7 patients. Br J Psychiatry 1964; 110: 505–513.
16. Raimo EB, Roemer RA, Moster M, et al. Alcohol-induced depersonalization. Biol Psychiatry 1999; 45: 1523–1526.
17. Cattell JP. Depersonalization phenomenon, in Arieti S (ed): American Handbook of Psychiatry. New York, Basic Books, 1972, pp 127–151.
18. Coons PM. Depersonalization and derealization, in Michelson LK, Ray WJ (eds): Handbook of Dissociation: Theoretical, Empirical, and Clinical Perspectives. New York, Plenum Press, 1996, pp 291–306.
19. Steinberg M. The spectrum of depersonalization: Assessment and treatment, in Tasman A, Goldfinger SM (eds): American Psychiatric Press Review of Psychiatry. Washington, DC, American Psychiatric Press, 1991, vol 10, pp 223–247.
20. Good MI. Substance-induced dissociative disorders and psychiatric nosology. J Clin Psychopharmacol 1989; 9: 88–93.
21. Stein MB, Uhde TW. Depersonalization disorder: Effects of caffeine and response to pharmacotherapy. Biol Psychiatry 1989; 26: 315–320.
22. Dunn GE, Paolo AM, Ryan JJ, et al. Dissociative symptoms in a substance abuse population. Am J Psychiatry 1993; 150: 1043–1047.
23. Black DW, Wojcieszek J. Depersonalization syndrome induced by fluoxetine. Psychosomatics 1991; 32: 468–469(letter).
24. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–210.
25. Hollander E, Cohen L, DeCaria C, et al. Fluoxetine and depersonalization syndrome. Psychosomatics 1992; 33: 361–362(letter).
26. Lear J, Moore RS. Acute psychiatric disturbance: A side effect of indomethacin therapy. J Accid Emerg Med 1994; 11: 210.
27. Schwartz JI, Moura RJ. Severe depersonalization and anxiety associated with indomethacin. South Med J 1983; 76: 679–680.
28. Abraham HD, Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996; 16: 238–241.
29. Szymanski HV. Prolonged depersonalization after marijuana use. Am J Psychiatry 1981; 138: 231–233.
30. Keshaven MS, Lishman WA. Prolonged depersonalization following cannabis abuse. Br J Addict 1986; 81: 140–142(letter).
31. Edwards G. Cannabis and the criteria for legalisation of a currently prohibited recreational drug: Groundwork for a debate. Acta Psychiatr Scand Suppl 1974; 251: 1–62.
32. Carney MW, Bacelle L, Robinson B. Psychosis after cannabis abuse. Br Med J (Clin Res Ed) 1984; 288: 1047.
33. Tennant FS Jr, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972; 27: 133–136.
34. Mathew RJ, Wilson WH, Humphreys D, et al. Depersonalization after marijuana smoking. Biol Psychiatry 1993; 33: 431–441.
35. Johnson BA. Psychopharmacological effects of cannabis. Br J Hosp Med 1990; 43: 114–122.
36. Moran C. Depersonalization and agoraphobia associated with marijuana use. Br J Med Psychol 1986; 59: 187–196.
37. Melges FT, Tinklenberg JR, Hollister LE, et al. Temporal disintegration and depersonalization during marihuana intoxication. Arch Gen Psychiatry 1970; 23: 204–210.
38. Simeon D, Hollander E, Stein DJ, et al. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiatry Res 1995; 58: 161–164.
39. Kellner M, Schick M, Wiedemann K. Prodissociative effects of metyrapone. Am J Psychiatry 2001; 158: 1159(letter).
40. Yehuda R, Levengood RA, Schmeidler J, et al. Increased pituitary activation following metyrapone administration in post-traumatic stress disorder. Psychoneuroendocrinology 1996; 21: 1–16.
41. Gump DW, Ashikaga T, Fink TJ, et al. Side effects of minocycline: Different dosage regimens. Antimicrob Agents Chemother 1977; 12: 642–646.
42. Terao T, Yoshimura R, Terao M, et al. Depersonalization following nitrazepam withdrawal. Biol Psychiatry 1992; 31: 212–213(letter).
43. Brogden RN, Avery GS. New antibiotics: Epicillin, minocycline and spectinomycin—A summary of their antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1972; 3: 314–330.
44. Brogden RN, Speight TM, Avery GS. Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 1975; 9: 251–291.
45. Allen JC. Minocycline. Ann Intern Med 1976; 85: 482–487.
46. Maibach H. Second-generation tetracyclines, a dermatologic overview: Clinical uses and pharmacology. Cutis 1991; 48: 411–417.
47. Parneix-Spake A, Bastuji-Garin S, Lobut JB, et al. Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol 1995; 131: 490–491(letter).
48. Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline: Report of 13 patients and review of the literature. Arch Dermatol 1996; 132: 934–939.View Full Text
49. Somech R, Arav-Boger R, Assia A, et al. Complications of minocycline therapy for acne vulgaris: Case reports and review of the literature. Pediatr Dermatol 1999; 16: 469–472.
50. Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: A systematic review. Dermatology 2000; 200: 223–231.
51. Meyerson MA, Cohen PR, Hymes SR. Lingual hyperpigmentation associated with minocycline therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 180–184.
52. Jonas M, Cunha BA. Minocycline. Ther Drug Monit 1982; 4: 137–145.
53. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224–1230.
54. Smilack JD. The tetracyclines. Mayo Clin Proc 1999; 74: 727–729.
55. Minocin (minocycline), in Physicians’ Desk Reference. Montvale, NJ, Medical Economics Co., 2002, ed 56, pp 1863–1865.
56. Dynacin (minocycline), in Physicians’ Desk Reference Montvale, NJ, Medical Economics Co., 2002, ed 56, pp 2019–2020.